Robert Debernardo

1.6k total citations
39 papers, 1.2k citations indexed

About

Robert Debernardo is a scholar working on Obstetrics and Gynecology, Surgery and Reproductive Medicine. According to data from OpenAlex, Robert Debernardo has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Obstetrics and Gynecology, 14 papers in Surgery and 11 papers in Reproductive Medicine. Recurrent topics in Robert Debernardo's work include Endometrial and Cervical Cancer Treatments (13 papers), Ovarian cancer diagnosis and treatment (9 papers) and Advanced Radiotherapy Techniques (7 papers). Robert Debernardo is often cited by papers focused on Endometrial and Cervical Cancer Treatments (13 papers), Ovarian cancer diagnosis and treatment (9 papers) and Advanced Radiotherapy Techniques (7 papers). Robert Debernardo collaborates with scholars based in United States, Italy and Russia. Robert Debernardo's co-authors include Lawrence M. Lichtenstein, Charles A. Kunos, Teruko Ishizaka, Hisao Tomioka, Steven Waggoner, Scott F. Sieg, Michael M. Lederman, Benigno Rodríguez, Nancy Fusco and James Brindle and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Robert Debernardo

35 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Debernardo United States 17 428 228 216 212 212 39 1.2k
Amal Kanbour‐Shakir United States 21 156 0.4× 224 1.0× 15 0.1× 189 0.9× 289 1.4× 55 1.2k
Masao Ichikawa Japan 13 728 1.7× 152 0.7× 42 0.2× 758 3.6× 93 0.4× 37 1.3k
A. Bohbot France 16 647 1.5× 362 1.6× 112 0.5× 141 0.7× 17 0.1× 40 1.1k
Tayfun Güngör Switzerland 26 842 2.0× 365 1.6× 24 0.1× 193 0.9× 27 0.1× 88 2.4k
Alain Gey France 19 1.1k 2.6× 281 1.2× 73 0.3× 983 4.6× 33 0.2× 37 1.7k
M. C. Mingari Italy 18 1.2k 2.8× 145 0.6× 34 0.2× 356 1.7× 67 0.3× 37 1.4k
C H Holmes United Kingdom 18 765 1.8× 233 1.0× 10 0.0× 74 0.3× 237 1.1× 27 1.3k
Yuri Fedoriw United States 23 331 0.8× 555 2.4× 103 0.5× 640 3.0× 18 0.1× 110 1.9k
Mattia Bugatti Italy 22 937 2.2× 344 1.5× 11 0.1× 457 2.2× 334 1.6× 55 1.8k
Amu Therwath France 16 167 0.4× 257 1.1× 114 0.5× 210 1.0× 13 0.1× 39 745

Countries citing papers authored by Robert Debernardo

Since Specialization
Citations

This map shows the geographic impact of Robert Debernardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Debernardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Debernardo more than expected).

Fields of papers citing papers by Robert Debernardo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Debernardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Debernardo. The network helps show where Robert Debernardo may publish in the future.

Co-authorship network of co-authors of Robert Debernardo

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Debernardo. A scholar is included among the top collaborators of Robert Debernardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Debernardo. Robert Debernardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vargas, Roberto, Aaron Petty, Daniel J. Lindner, et al.. (2025). Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer. npj Precision Oncology. 9(1). 290–290.
2.
3.
O’Cearbhaill, Roisin E., Austin Miller, Robert A. Soslow, et al.. (2023). A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecologic Oncology. 176. 16–24. 3 indexed citations
4.
Piñeiro, Ana Otero, Jessica Philpott, Amy L. Lightner, et al.. (2022). Entero-Gynecologic Fistula: A Rare Complication of Penetrating Crohn’s Disease. Journal of Gastrointestinal Surgery. 27(2). 413–415.
5.
Vargas, Roberto, Priyanka Gopal, Robert Debernardo, et al.. (2018). Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. npj Precision Oncology. 2(1). 14–14. 19 indexed citations
6.
Kunos, Charles A., Rodney J. Ellis, Simon S. Lo, et al.. (2015). Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer. Frontiers in Oncology. 5. 126–126. 19 indexed citations
7.
Mahdi, Haider, Joanne Xiu, Sandeep K. Reddy, & Robert Debernardo. (2015). Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. Journal of Surgical Oncology. 112(2). 188–194. 15 indexed citations
8.
9.
Debernardo, Robert, et al.. (2013). Management of Early Stage, High-Risk Endometrial Carcinoma: Preoperative and Surgical Considerations. Obstetrics and Gynecology International. 2013. 1–7. 5 indexed citations
10.
Hardy, Gareth, Scott F. Sieg, Benigno Rodríguez, et al.. (2013). Interferon-α Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers. PLoS ONE. 8(2). e56527–e56527. 121 indexed citations
11.
12.
Kunos, Charles A., Tomas Radivoyevitch, Steven Waggoner, et al.. (2013). Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecologic Oncology. 130(1). 75–80. 74 indexed citations
13.
Kunos, Charles A., James Brindle, & Robert Debernardo. (2012). Stereotactic Radiosurgery for Gynecologic Cancer. Journal of Visualized Experiments. 4 indexed citations
14.
Kunos, Charles A., James Brindle, Steven Waggoner, et al.. (2012). Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies. SHILAP Revista de lepidopterología. 2. 181–181. 69 indexed citations
15.
Kunos, Charles A., et al.. (2012). Hematological Toxicity After Robotic Stereotactic Body Radiosurgery for Treatment of Metastatic Gynecologic Malignancies. International Journal of Radiation Oncology*Biology*Physics. 84(1). e35–e41. 10 indexed citations
16.
Starks, David, et al.. (2011). Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report. Case Reports in Obstetrics and Gynecology. 2011. 1–2. 4 indexed citations
17.
Gruenigen, Vivian von, Heidi E. Frasure, Nancy Fusco, et al.. (2010). A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patients. Cancer. 116(20). 4735–4743. 43 indexed citations
18.
Hensley, Martee L., Michael W. Sill, Dennis R. Scribner, et al.. (2009). Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. Gynecologic Oncology. 115(3). 460–465. 71 indexed citations
19.
Debernardo, Robert, Ramey D. Littell, Huaxiu Luo, et al.. (2005). Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biology & Therapy. 4(1). 110–114. 16 indexed citations
20.
Debernardo, Robert, Rebecca B. Perkins, Ramey D. Littell, Carolyn Krasner, & Linda Duska. (2005). Low-Molecular-Weight Heparin (Dalteparin) in Women With Gynecologic Malignancy. Obstetrics and Gynecology. 105(5, Part 1). 1006–1011. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amal Kanbour‐Shakir Breakdown of academic impact, for papers by Masao Ichikawa Breakdown of academic impact, for papers by A. Bohbot Breakdown of academic impact, for papers by Tayfun Güngör Breakdown of academic impact, for papers by Alain Gey Breakdown of academic impact, for papers by M. C. Mingari Breakdown of academic impact, for papers by C H Holmes Breakdown of academic impact, for papers by Yuri Fedoriw Breakdown of academic impact, for papers by Mattia Bugatti Breakdown of academic impact, for papers by Amu Therwath
Rankless by CCL
2026